tiprankstipranks
Advertisement
Advertisement
Humacyte price target lowered to $1 from $3 at Piper Sandler
PremiumThe FlyHumacyte price target lowered to $1 from $3 at Piper Sandler
14d ago
Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating
Premium
Ratings
Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating
14d ago
Morning Movers: AstraZeneca jumps following tozorakimab trial results
Premium
The Fly
Morning Movers: AstraZeneca jumps following tozorakimab trial results
17d ago
Humacyte Ends ATM Program, Highlights Symvess Global Expansion
PremiumCompany AnnouncementsHumacyte Ends ATM Program, Highlights Symvess Global Expansion
25d ago
Humacyte prices $20M registered direct offering
Premium
The Fly
Humacyte prices $20M registered direct offering
25d ago
Humacyte receives Symvess purchase commitment
Premium
The Fly
Humacyte receives Symvess purchase commitment
25d ago
Humacyte price target lowered to $10 from $11 at Benchmark
PremiumThe FlyHumacyte price target lowered to $10 from $11 at Benchmark
3M ago
Humacyte announces data from analysis of charges for extremity arterial injury
Premium
The Fly
Humacyte announces data from analysis of charges for extremity arterial injury
3M ago
Humacyte announces planned MAA for Symvess in Israel
Premium
The Fly
Humacyte announces planned MAA for Symvess in Israel
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100